The Canna Law Blog is a forum for discussing the practical aspects of cannabis law and its impacts on the cannabis industry. We provide insight into how cannabis businesspeople can use the law to their advantage and in plain language we tell you what works and what does not. We aim to help you strategize how to wield the law as both a shield and a sword.
Amanita muscaria (also known as fly agaric) is a type of mushroom with hallucinogenic properties. It is also not listed on any schedule of the Controlled Substances Act (CSA). So of course, people want to make and sell it. But what is it? And is it legal? Amanita muscaria (fly agaric) Amanita muscaria is a
In the next few years, the FDA will likely approve drug formulations containing psilocybin and MDMA. While there are still many unknowns concerning how psilocybin and MDMA-based drug therapies will be regulated, we believe that many of the same trends we have seen over the last few years in ketamine therapy will apply to these
Over the last year and change, I’ve written quite a bit about how the ketamine telehealth industry was in store for a rude awakening when the COVID-19 public health emergency (PHE) declaration ended. My most recent post, entitled “Bad News for Ketamine Telehealth” predicted an imminent shakeup in the industry due to the looming end
Last summer, my colleague, Ethan Minkin, published a post entitled “Utah Ketamine Clinics Face New Patient Monitoring Law.” The law in question applied a host of new requirements on anesthesia or sedation providers, which created a series of hurdles for ketamine clinics. A few weeks ago, a Utah state legislator submitted a bill that would
Earlier this week, President Joe Biden’s administration made an announcement that signals potential bad news for the ketamine telehealth industry. Effective May 11, 2023, the federal COVID-19 public health emergency (PHE) declaration will end. This is likely to plunge the entire ketamine telehealth industry into chaos in the coming months. If you are unfamiliar with
Since Denver became the first U.S. jurisdiction to decriminalize psilocybin in 2019, a number of cities across the country – including, most notably, Oakland and Santa Cruz in California – have decriminalized psychedelics in various forms. And as readers of the Psychedelics Law Blog are surely aware, Oregon and now Colorado passed full-scale regulatory regimes.
There’s been a lot of news about Tuesday’s election. One of the things that hasn’t made the waves is Colorado’s approval of Prop. 122, which will pave the way for psilocybin clinics like in Oregon. Prop. 122 is actually much broader than Oregon’s Measure 109, and legalizes psychedelics far beyond just psilocybin. Many expressed opposition
Last week, we presented a psychedelics webinar entitled “How to Protect Your Psychedelics Business.” The panelists were Paul Coble, me (Griffen Thorne from our Los Angeles office), and Graham Pechenik of Calyx Law in San Francisco. In the webinar, we presented on business law and intellectual property issues that will affect new psychedelics businesses in
Next month, Colorado voters will decide the fate of Proposition 122, named the Natural Medicine Health Act of 2022 (NMHA). If passed, NHMA would legalize a host of psychedelics in Colorado. Today, we’ll look at what NMHA would do. Natural Medicine Health Act of 2022 NMHA is modeled on – or at least influenced by
Our psychedelics team routinely fields questions from non-Oregon residents looking for Oregon psilocybin licenses. However, one of Measure 109‘s more infamous requirements is its residency requirement. These provisions require that, until January 1, 2025, manufacturing facilities and service centers must have majority ownership by individual(s) who have resided in Oregon for at least two years.
